EMAIL THIS PAGE TO A FRIEND

Acta neuropathologica

Non-steroidal anti-inflammatory drug indometacin enhances endogenous remyelination.


PMID 25943886

Abstract

Multiple sclerosis is the most frequent demyelinating disease in the CNS that is characterized by inflammatory demyelinating lesions and axonal loss, the morphological correlate of permanent clinical disability. Remyelination does occur, but is limited especially in chronic disease stages. Despite effective immunomodulatory therapies that reduce the number of relapses the progressive disease phase cannot be prevented. Therefore, promotion of neuroprotective and repair mechanisms, such as remyelination, represents an attractive additional treatment strategy. A number of pathways have been identified that may contribute to impaired remyelination in MS lesions, among them the Wnt/β-catenin pathway. Here, we demonstrate that indometacin, a non-steroidal anti-inflammatory drug (NSAID) that has been also shown to modulate the Wnt/β-catenin pathway in colorectal cancer cells promotes differentiation of primary human and murine oligodendrocytes, myelination of cerebellar slice cultures and remyelination in cuprizone-induced demyelination. Our in vitro experiments using GSK3β inhibitors, luciferase reporter assays and oligodendrocytes expressing a mutant, dominant stable β-catenin indicate that the mechanism of action of indometacin depends on GSK3β activity and β-catenin phosphorylation. Indometacin might represent a promising treatment option to enhance endogenous remyelination in MS patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A5376
Acetylsalicylic acid, ≥99.0%
C9H8O4
A3160
Acetylsalicylic acid, analytical standard
C9H8O4
A2093
Aspirin, meets USP testing specifications
C9H8O4
L4408
Lithium chloride, BioXtra, ≥99.0% (titration)
ClLi
62476
Lithium chloride, BioUltra, for molecular biology, anhydrous, ≥99.0% (AT)
ClLi
L9650
Lithium chloride, for molecular biology, ≥99%
ClLi
429457
Lithium chloride, anhydrous, beads, −10 mesh, 99.998% trace metals basis
ClLi
449881
Lithium chloride, anhydrous, beads, −10 mesh, ≥99.9% trace metals basis
ClLi
203637
Lithium chloride, powder, ≥99.98% trace metals basis
ClLi
L7026
Lithium chloride solution, 8 M, for molecular biology, ≥99%
ClLi
694576
Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone
ClLi
667544
Lithium chloride solution, 0.5 M in anhydrous tetrahydrofuran
ClLi
EHU006141 MISSION® esiRNA, esiRNA targeting human PDGFRA (esiRNA1)
RDD004
PIPES, anhydrous, free-flowing, Redi-Dri, ≥99%
C8H18N2O6S2
P6757
PIPES, ≥99% (titration)
C8H18N2O6S2
RES0703P-A7
PIPES, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, suitable for cell culture
C8H18N2O6S2
P1851
PIPES, BioPerformance Certified, suitable for cell culture
C8H18N2O6S2
P8203
PIPES, BioXtra, ≥99% (titration)
C8H18N2O6S2
80635
PIPES, BioXtra, for molecular biology, ≥99.5% (T)
C8H18N2O6S2